|
|
| (22 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| {{Ventilator-associated pneumonia}}
| | #redirect[[Hospital-acquired pneumonia]] |
| {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh@perfuse.org]
| |
| ==[[Ventilator-associated pneumonia overview|Overview]]==
| |
| ==[[Ventilator-associated pneumonia historical perspective|Historical Perspective]]==
| |
| ==[[Ventilator-associated pneumonia pathophysiology|Pathophysiology]]==
| |
| ==[[Ventilator-associated pneumonia causes|Causes]]==
| |
| ==[[Pneumonia differential diagnosis|Differential diagnosis]]==
| |
| | |
| ==[[Pneumonia epidemiology and demographics|Epidemiology and Demographics]]==
| |
| ==[[Ventilator-associated pneumonia risk factors|Risk Factors]]==
| |
| ==[[Pneumonia natural history, complications, and prognosis|Natural History, Complications and Prognosis]]==
| |
| '''Prognosis predictor scores:''' [[CURB-65]] | [[Pneumonia severity index]] | [[Pneumonia medical therapy#Criteria for severe community acquired pneumonia|Criteria for severe community acquired pneumonia]]
| |
| | |
| ==Diagnosis==
| |
| [[Ventilator-associated pneumonia diagnostic criteria|Diagnostic criteria]] | [[Ventilator-associated pneumonia history and symptoms| History and Symptoms]] | [[Pneumonia physical examination | Physical Examination]] | [[Ventilator-associated pneumonia laboratory studies |Laboratory Findings]] | [[Pneumonia chest x ray|Chest X Ray]]
| |
| | |
| ==Treatment==
| |
| | |
| [[Ventilator-associated pneumonia medical therapy|Medical Therapy]] [[Ventilator-associated pneumonia prevention|Prevention]]
| |
| [[Category:Diseaase]]
| |
| [[Category:Pulmonology]]
| |
| [[Category:Infectious disease]]
| |
| [[Category:Pneumonia|Pneumonia]]
| |
| [[Category:Emergency medicine]]
| |
| | |
| {{WH}}
| |
| {{WS}}
| |
| | |
| == Epidemiology and prognosis ==
| |
| VAP occurs in up to 25% of all people who require mechanical ventilation. VAP can develop at any time during ventilation, but occurs more often in the first few days after intubation. This is because the intubation process itself contributes to the development of VAP. VAP occurring early after intubation typically involves fewer resistant organisms and is thus associated with a more favorable outcome. Because respiratory failure requiring mechanical ventilation is itself associated with a high mortality, determination of the exact contribution of VAP to mortality has been difficult. As of [[2006]], estimates range from 33% to 50% death in patients who develop VAP. Mortality is more likely when VAP is associated with certain microorganisms (''Pseudomonas'', ''Acinetobacter''), [[Bacteremia|blood stream infections]], and ineffective initial antibiotics. VAP is especially common in people who have [[acute respiratory distress syndrome]] (ARDS).
| |
| == See also ==
| |
| * [[Pneumonia]]
| |
| * [[Nosocomial infection]]
| |
| == References ==
| |
| * {{cite journal | author=American Thoracic Society and the Infectious Diseases Society of America. | title=ATS/IDSA Guidelines: Guidelines for the management of adults with HAP, VAP, and HCAP | journal=Am J Respir Crit Care Med | year=2005 | volume=171 | pages=388 }}
| |
| [[Category:Pneumonia]]
| |
| [[Category:Pulmonology]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WS}}
| |